Schizophrenia Research
Volume 120, Issue 1 , Pages 199-203 , July 2010

Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia

  • J.P. Docherty

      Affiliations

    • Weill-Cornell Medical College, White Plains, NY, USA
    • Corresponding Author InformationCorresponding author. Weill-Cornell Medical College, 21 Bloomingdale Road, White Plains, NY 10605, USA. Tel.: +1 914 843 2541; fax: +1 914 234 7733.
    • ,
  • R.A. Baker

      Affiliations

    • Bristol-Myers Squibb, Plainsboro, NJ, USA
    • ,
  • J. Eudicone

      Affiliations

    • Bristol-Myers Squibb, Plainsboro, NJ, USA
    • ,
  • S. Mathew

      Affiliations

    • Otsuka America Pharmaceutical Inc., Rockville, MD, USA
    • ,
  • R.N. Marcus

      Affiliations

    • Bristol-Myers Squibb, Wallingford, CT, USA
    • ,
  • R.D. McQuade

      Affiliations

    • Otsuka Pharmaceutical Development and Commercialization Inc., Princeton, NJ, USA
    • ,
  • R. Mankoski

      Affiliations

    • Bristol-Myers Squibb, Plainsboro, NJ, USA

Received 23 November 2009 ,Accepted 31 March 2010.

References 

  1. Baran X, Docherty J. The A-effect of aripiprazole. In: Presented at the American Psychiatric Association meeting. 2008;Washington, May 3–8 2008
  2. Barrowclough C, Tarrier N. Social functioning in schizophrenic patients. I. The effects of expressed emotion and family intervention. Soc. Psychiatry Psychiatr. Epidemiol. 1990;25(3):125–129
  3. Bellack AS, Green MF, Cook JA, Fenton W, Harvey PD, Heaton RK, et al. Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr. Bull. 2007;33(3):805–822
  4. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 2002;302(1):381–389
  5. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 2002;346(1):16–22
  6. Girgis, R., Merrill, D., Vorel, S., Kim, E., Portland, K., You, M., Pikalov, A., Whitehead, R. and Lieberman, J., submitted for publication. Aripiprazole versus haloperidol treatment in early-stage schizophrenia. J. Psychiatr. Res.
  7. Grant C, Addington J, Addington D, Konnert C. Social functioning in first- and multiepisode schizophrenia. Can. J. Psychiatry. 2001;46(8):746–749
  8. Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, et al. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J. Clin. Psychiatry. 2009;70(1):25–35
  9. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur. J. Pharmacol. 2002;441(3):137–140
  10. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. 2004;483(1):45–53
  11. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry. 2002;63(9):763–771
  12. Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J. Clin. Psychiatry. 2007;68(2):213–223
  13. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 2003;6(4):325–337
  14. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole (STAR) Study. Eur. Psychiatry. 2007;22(7):433–443
  15. Kim, E., Eudicone, J., Portland, K. and Pikalov, A., 2007. Efficacy of aripiprazole versus haloperidol in early episode schizophrenia. Presented at the American Psychiatric Association 160th Annual Meeting, San Diego, CA, May 19–24, 2007. NR283.
  16. Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am. J. Psychiatry. 2003;160(8):1405–1412
  17. Mizrahi R, Mamo D, Rusjan P, Graff A, Houle S, Kapur S. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int. J. Neuropsychopharmacol. 2009;12(5):715–721
  18. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J. Clin. Psychiatry. 2003;64(9):1048–1056
  19. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2003;60(7):681–690
  20. Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int. J. Neuropsychopharmacol. 2009;12(9):1233–1248
  21. Purnine DM, Carey KB, Maisto SA, Carey MP. Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders. J. Nerv. Ment. Dis. 2000;188(10):653–661
  22. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol. 2003;28(8):1400–1411
  23. Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T, et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur. J. Pharmacol. 2005;515(1–3):10–19
  24. Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors. Eur. J. Pharmacol. 2008;597(1–3):27–33
  25. Wolf J, Janssen F, Lublin H, Salokangas RK, Allain H, Smeraldi E, et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr. Med. Res. Opin. 2007;23(10):2313–2323
  26. Yager JA, Ehmann TS. Untangling social function and social cognition: a review of concepts and measurement. Psychiatry. 2006;69(1):47–68

PII: S0920-9964(10)01220-X

doi: 10.1016/j.schres.2010.03.040

Schizophrenia Research
Volume 120, Issue 1 , Pages 199-203 , July 2010

Article Tools

* Image Usage & Resolution